Trials / Completed
CompletedNCT00171886
Octreotide Efficacy and Safety in First-line Acromegalic Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Primary Acromegaly is a clinical and metabolic disease caused by growth hormone (GH) hypersecretion from a pituitary adenoma and is an insidious, chronic disease that is associated with bony and soft tissue overgrowth. Goals of therapy are to eradicate the tumor, suppress GH secretion, normalize IGF-I levels, and preserve normal pituitary function. This study will evaluate the safety and efficacy of octreotide as primary therapy for the treatment of acromegaly and as therapy for patients with acromegaly and a pituitary macroadenoma or microadenoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Octreotide |
Timeline
- Start date
- 2002-07-01
- Primary completion
- 2006-05-01
- Completion
- 2006-05-01
- First posted
- 2005-09-15
- Last updated
- 2017-02-24
Locations
8 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00171886. Inclusion in this directory is not an endorsement.